Sofosbuvir in Treatment of COVID 19

Phase 2

• Conditions: COVID
• Interventions: Drug: sofosbuvir; Drug: Sofosbuvir ledipsavir; Drug: Daclatasvir

• Registration Number: NCT04460443
• Lead Sponsor: Tanta University

Brief Summary

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

Detailed Description

Sofosbuvir containing treatment of COVID 19 Egyptian patients: a randomized-controlled trial

Study Timeline

• Study First Submitted: 2020-07-04
• Study First Submitted QC: 2020-07-04
• Study First Posted: 2020-07-07
• Study Start: 2020-08-01
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-03
• Last Update Posted: 2020-12-08
• Primary Completion: 2021-08-01
• Study Completion: 2021-08-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Covid positive patients.

Exclusion Criteria

• Contraindication to sofosbuvir or ribavirin.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sofosbuvir and Daklatasuvir	sofosbuvir	Sofosbuvir and Daklatasuvir plus standard of card treatment..
Sofosbuvir and ledipsavir	Sofosbuvir ledipsavir	Sofosbuvir and ledipsavir plus standard of care treatment.
Sofosbuvir and Daklatasuvir	Daclatasvir	Sofosbuvir and Daklatasuvir plus standard of card treatment..

Primary Outcome Measures

Name	Time	Method
Number of patients with response to treatment	1 month	The total number of patients with response to treatment

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Tanta, Egypt